Squamous cell lung cancer represents a distinct molecular pathologic NSCLC with unmet therapeutic needs, especially after failure of first-line platinum-based doublet chemotherapy.
This article is Part III of a series. View parts I and II:Evolving Paradigms in Squamous NSCLC> >
Brown Examines Lenvatinib/Pembrolizumab Combination in pMMR Endometrial Cancer
May 17th 2024During a Case-Based Roundtable® event, Jubilee Brown, MD, discussed the efficacy and safety data from the KEYNOTE-775/Study 309 trial of lenvatinib plus pembrolizumab in patients with mismatch repair proficient advanced endometrial cancer.
Read More